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Introduction
Real-time molecular imaging has the potential to reveal the
dynamics of β cell mass (BCM) in diabetes [1, 2]. We have
hypothesized that the vesicular monoamine transporter,
type 2 (VMAT2) might be a useful β cell target for
longitudinal quantification by PET performed to obtain
estimates of changes in BCM rather than absolute values
[3–6]. Supporting this concept are reports documenting
that (1) there exists an approximate five-fold natural
variation in beta cell mass among healthy individuals [7];
(2) within the pancreas, VMAT2 co-localizes with insulin
in β cells as determined by immunohistochemistry [8, 9];
(3) the pancreatic expression of VMAT2 closely parallels β
cell insulin immunoreactivity in diabetic disease [10]; (4)
there is a loss of VMAT2 signal paralleling the
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Abstract
Purpose: The vesicular monoamine transporter, type 2 (VMAT2) is expressed by insulin
producing β cells and was evaluated as a biomarker of β cell mass (BCM) by positron emission
tomography (PET) with [18F]fluoropropyl-dihydrotetrabenazine ([18F]FP-(+)-DTBZ).
Procedures: We evaluated the feasibility of longitudinal pancreatic PET VMAT2 quantification in
the pancreas in two studies of healthy controls and patients with type 1 or 2 diabetes. VMAT2
binding potential (BPND) was estimated voxelwise using a reference tissue method in a cross-
sectional study, followed by assessment of reproducibility using a test-retest paradigm.
Metabolic function was evaluated by stimulated c-peptide measurements.
Results: Pancreatic BPND was significantly decreased in patients with type 1 diabetes relative to
controls and the test-retest variability was 9.4 %.
Conclusions: Pancreatic VMAT2 content is significantly reduced in long-term diabetes patients
relative to controls and repeat scans are sufficiently reproducible to suggest the feasibility
clinically VMAT2 measurements in longitudinal studies of new onset diabetes.
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Age (years) 27.5±1.4 29.4±4.3 55.0±3.5*
Gender (male/female) 9:5 4:4 2:1
Weight (kg) 70.5±2.7 75.2±4.0 95.8±10.9*
Body mass index (kg/m2) 23.5±0.5 25.3±0.9 31.4±0.3*
Hemoglobin A1c (%) 5.0±0.1 7.1±0.2** 7.0±0.1*
Insulin dose/day (units/kg/day) N/A 0.57±0.05 1.24c
Duration of diabetes (years) N/A 18.5±2.8 11.7±2.4
Estimated glomerular filtration





aControls: n=9 for cross-sectional study and n=5 for test-retest study
bT1DM patients: n=6 for cross-sectional study and n=2 for test-retest study
c1 of 3 with T2DM requiring insulin
*pG0.01, control vs. T2DM
**pG0.01, control vs. T1DM
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development of hyperglycemia and β cell loss in preclin-
ical PET studies using rodent models of diabetes [3, 4, 11,
12]; (5) dihydrotetrabenazine (DTBZ)-based positron
emission tomography (PET) radiotracers bind to VMAT2
with high affinity (i.e., Kd in the subnanomolar range) [5,
12–17] and selectivity [5, 18]; and (6) DTBZ-based PET
tracers are useful in longitudinal studies requiring VMAT2
quantification in the central nervous system [19]. Addi-
tionally, we previously reported [11C]dihydrotetrabenazine
([11C]DTBZ) pancreatic PET uptake in humans with or
without long-standing type 1 diabetes mellitus (T1DM)
[20]. In this latter study, pancreatic binding of [11C]DTBZ
was significantly reduced in subjects with long-standing
T1DM compared to healthy controls.
M o r e r e c e n t l y , r e s e a r c h e r s d e v e l o p e d
[18F]fluoropropyl-dihydrotetrabenazine ([18F]FP-(+)-
DTBZ), which by virtue of its 120-min half-life and
higher affinity binding to VMAT2 [13, 15], provides
very high-quality PET images [21], allowing more
accurate VMAT2 quantification relative to [11C]DTBZ.
In this report, we document the results of a cross-
sectional study of pancreatic VMAT2 in healthy controls
and patients with T1DM and type 2 diabetes mellitus
(T2DM) using PET with [18F]FP-(+)-DTBZ to estimate
pancreatic BCM. To our knowledge, this is the first
study evaluating VMAT2 in T2DM. Additionally, this
study is the first to describe the reproducibility of
pancreatic [18F]FP-(+)-DTBZ uptake measurements in
human pancreata.
Materials and Methods
This PET study was performed under the supervision of the
Columbia University Medical Center Institutional Review Board
and in accordance with the precepts established by the Helsinki
Declaration. Our study was divided into two separate arms. The
first arm evaluated [18F]FP-(+)-DTBZ pancreatic PET uptake in
healthy controls and patients with T1DM or T2DM. The second
arm evaluated the test-retest variability of VMAT2 quantification
by PET scans with [18F]FP-(+)-DTBZ. In this segment, healthy
controls and patients with T1DM underwent a second PET scan
within 4 weeks of the first.
Subjects
Twenty-five subjects completed the study; this included 14
healthy controls, 8 subjects with long-standing T1DM, and 3
subjects with T2DM. Healthy control subjects were excluded if
fasting glucose levels were greater than 100 mg/dl or if there
was a first-degree relative with T2DM. Subjects with diabetes
were required to have been diagnosed at least 5 years prior to
enrollment. Patients with diabetes were excluded if microvas-
cular complications were present. Demographic and laboratory
data are summarized in Table 1.
Metabolic Testing
All subjects underwent mixed meal tolerance testing (MMTT). A 2-
h MMTT was used to assess insulin production capacity, an
indirect marker of BCM. Prior to undergoing MMTT testing,
patients fasted for at least 6 h. Insulin was discontinued in all
subjects with diabetes prior to testing; glucose levels ranged
between 70 and 200 mg/dl before study start. No insulin was
administered within 2 h of testing. In those using continuous insulin
infusion therapies, basal rates were suspended 30 min prior to
testing. Two-hour MMTT was performed as per previous published
reports [20, 22]. Venous serial samples were assayed for glucose
(mg/dl), insulin (μIU/ml), and c-peptide (ng/ml) by previously
described standard methods [20]. The peak c-peptide and area
under the curve (AUC) c-peptide values were calculated as
previously reported [20].
PET Radiotracer
[18F]FP-(+)-DTBZ was synthesized as described previously [12]. In
the first part of the study, [18F]FP-(+)-DTBZ was synthesized by
AVID Radiopharmaceuticals Ltd. (Philadelphia, PA). [18F]FP-(+)-
DTBZ was synthesized at the Kreitchman PET center of Columbia
University in the second part of study, which included the test-
retest segment.
PET Scans
All subjects were studied after an overnight fast. Type 1 diabetic
subjects were instructed to not take their usual morning insulin
dose. Patient blood glucose was monitored before and during the
scan and insulin dosages were adjusted as needed to maintain
glucose values between 70 and 200 mg/dl. Heart rate, blood
pressure, and electrocardiogram were monitored continuously
throughout the imaging procedure. Subjects were scanned lying
Fig. 1 Sagittal slice by slice analysis of pancreatic VMAT2
binding obtained by parametric mapping of BPND. A repre-
sentative slice by slice analysis of VMAT2 binding in a
healthy control pancreas, represented as the total volume
of voxels with a BPND90.1 (circles), the average BPND of
those voxels (squares) and the product of the voxel volume
and mean BPND of the slice (triangles). Y axis; since BPND is
dimensionless, there are no units on this axis. X-axis, the
corresponding slice number starting at the head of the
pancreas ending at the tail. The demarcation of head and
combined body-tail of the pancreas was taken as the first
local minima (from left to right) of mean BPND × total voxel
volume.
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supine on a Biograph mCT PET/CT camera (Siemens Medical
Solutions USA, Inc., Malvern, PA) with reconstructed spatial
resolution of approximately 6 mm. Data acquisition occurred over a
period of up to 180 min. A low-dose abdominal computerized
tomography (CT) scan, guided by the CARE Dose4D program
(120 kV, 50–350 mA), was performed at the beginning of each
session for the collection of attenuation mapping and anatomical
data (matrix size=512×512×74 and voxel size=0.98×0.98×3.0 mm).
Dynamic PET measurements were acquired in list mode over an
axial field of that covered 22 cm beginning near the xiphoid
process and extending caudally over the abdomen. [18F]FP-(+)-
DTBZ (mean dose of 333±44 MBq) was administered as a bolus
over 2–3 min immediately after the start of the scan. The mean
specific activity of [18F]FP-(+)-DTBZ at the time of injection was
158±45 MBq nmol−1. There were no significant differences
between control and patients with diabetes in injected radioactivity
or mass of tracer. List mode-acquired PET data were reconstructed
into 22 (2 h) or 28 (3 h) dynamic frames with increasing frame
duration using a Hann-filtered back-projection algorithm with CT-
based attenuation, time-of-flight scatter, random, scanner dead time,
detector normalization, and radioactive decay corrections as
provided by the manufacturer’s software. The final reconstructed
images had a matrix size of 168×168×74 and a voxel size of
4.07×4.07×3.0 mm. For the test-retest studies, PET scans were
performed as described earlier with the exception of extending the
total scanning period to 180 min and subjects returned within
4 weeks for a second scan.
Quantification of Pancreatic VMAT2 Binding
The rationale and validity of applying voxelwise reference tissue,
kinetic model-based quantification of pancreas VMAT2 by PET
with [11C]DTBZ or [18F]FP-(+)-DTBZ has been previously
documented [2, 5, 20, 21]. VMAT2 binding data analysis was
performed using PET data analysis software by PMOD (PMOD
Technologies LTD., version 3.5, Zurich, Switzerland). Reconstruct-
ed abdominal CT images were manually realigned if needed to
correct for any visually detectable deviation from the anatomical
position of the abdomen in three orthogonal planes. This
individualized realignment transformation matrix was applied to
dynamic PET data to ensure abdominal PET images were aligned
in anatomical position. Then, abdominal CT images were
coregistered to the summed realigned PET images over the initial
30 min for each subject. On the fused CT and summed PET images
through multiple slices on the transaxial plane, volumes of interest
were manually placed of over the spleen (approximately 130 cm3 in
size). Time-activity curves (TACs) of the spleen were obtained by
applying this volume-of-interest (VOI) on the dynamic PET
images. Using the spleen as reference tissue input, voxelwise
parametric images of VMAT2 binding potential, BPND, which is
linearly proportional to the VMAT2 density (Bavail), were generated
by using the reference tissue model, MRTMO in PMOD [20, 23].
On the sagittal slices of BPND parametric images coregistered on
the sagittal CT images, VOIs were placed over the pancreas using a
threshold value of BDND90.1 and mean BPND values for each
sagittal slice of the pancreas were plotted allowing a clear
delineation of the head and combined body-tail of the pancreas
(Fig. 1). Using this information, we calculated the PET region-of-
interest (ROI) volume (total and combined body and tail), mean
BPND of the whole pancreas, and mean BPND for the combined
body and tail of the pancreas (Table 2).
VMAT2 Binding Comparisons
Previously, we documented that VMAT2 expression more closely
paralleled beta cell insulin expression in the body and tail of the
pancreas [8]. The PET-estimated VMAT2 binding in the pancreas
was compared between patient and control groups in two ways. The
first comparison metric was the mean BPND value calculated over
the combined body and tail of the pancreas. To better estimate the
total beta cell mass, we calculated a second metric, the functional
binding capacity (FBC) [20]. The FBC represents the sum of all
individual pancreatic voxel BPND values greater than 0.1 multiplied
by the total voxel volume (i.e., PET ROI volume) of the combined
body-tail of the pancreas. These metrics were calculated for each
subject and the group means calculated and compared.
VMAT2 and Insulin Expression in Human
Pancreatic Tissues
Islets, Exocrine Tissue, and Preparation of Total RNAThe
islet and exocrine pancreas tissue used in these studies were
historical samples obtained with institution review board approval
from the New York Regional Islet Cell Resource Center at New
York Presbyterian Hospital, Columbia Presbyterian Campus. The
isolation of islets and exocrine tissue and preparation of total RNA
was previously described [6]. Human pancreas total RNA indicated
as Pancreas 060 (Catalog Item 540024, LOT 06046024) was
obtained from Agilent Technologies (Santa Clara, CA). Human
pancreas total RNA, from a different individual, indicated as
Table 2. VMAT2 binding estimates with accompanying β cell function (stimulated AUC c-peptide and peak c-peptide) measurements
Controls-cross-sectional β cell function Pancreas body and taila
AUCb Peakc PET ROI volume (ml) Mean BPND BPND × volume (ml)
d
Subject study number
3001 347 4.9 50.5 1.97 99
3002 550 5.6 38.3 1.65 63
3004 557 7.7 83.3 2.92 243
3005 463 4.9 42.1 2.4 101
3006 372 4.1 53.5 1.79 96
3007 1056 14.0 49.7 2.25 112
3008 572 7.7 48.3 2.45 118
3009 558 6.4 43.5 2.12 92
3010 864 11.6 30.2 1.84 56
Controls-test-retest
4001 teste 57 0.79
4001 retest 22.4 2.644 59.4
4002 test 268 4.4 29.7 2.93 87
4002 retest 32.4 3.08 100
4004 test 407 9.0 32.3 3.18 103
4004 retest 27.6 2.95 81
4005 test 313 8.3 34.3 2.99 103
4005 retest 28.4 2.71 77
4006 test 104 1.2 27.0 2.67 72
4006 retest 30.7 2.97 91
T1DM-cross-sectional
T1D-3001 0.50 0.1 24.3 1.17 29
T1D-3002 0.50 0.1 27.5 1.43 39
T1D-3004 0.50 0.1 26.5 1.85 49
T1D-3005 0.50 0.1 16.3 1.32 22
T1D-3006 0.50 0.1 32.3 1.09 35
T1D-3007 0.5 0.1 14.5 1.86 27
T1DM-test-retest
T1D-4007 test 68 0.74 13.2 2.22 29
T1D-4007 retest 12.3 2.62 32
T1D-4008 test 49 .64 22.8 3.09 71
T1D-4008 retest 24.5 2.89 71
T2DM-cross-sectional
T2D-3001 393 4.52 19.2 1.66 32
T2D-3002 623 4.06 36.2 2.76 100
T2D-3003 1128 9.06 35.4 1.37 49
aAs defined in Fig. 1
bAUC insulin c-peptide (ng/ml × minutes)
cPeak insulin c-peptide concentration (ng/ml) taken from highest serum value from the serial blood draws following the mixed meal stimulus (MMTT).
dAlso referred to in the text as the functional binding capacity
eSubject did not successfully complete the first scan. These data used only in Fig. 3
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Pancreas 141 (Catalog Item 636577, LOT 1412464A) was been
obtained from Clontech Laboratories, Inc. (Mountain View, CA).
Total RNA from islets or purified acinar tissue was isolated using
the RNA RNeasy Lipid Tissue Mini Kit (QIAGEN, Valencia, CA).
Quantitative Analysis of VMAT2 and INS Transcripts by RT-
PCRFirst-strand cDNA synthesis using 400 ng of total RNA as
template was obtained using the QuantiTect Reverse Transcription
Kit (QIAGEN, Valencia, CA). PCRs executed to measure the
accumulation of specific transcripts were performed using as
template the amount of cDNA obtained retro-transcribing 10 ng
of RNA for β actin (ACTB) and Insulin (INS) and 40 ng of RNA
for VMAT2. The QuantiTect SYBR Green PCR Kit (QIAGEN)
was used to perform all the real-time quantitative PCR assays with
annealing temperatures of 55–60 °C and extension times of 30–
45 s, depending on the couple of primers used. Accumulation of
specific transcripts was measured by real-time PCR, using the
SmartCycler System (Cepheid, Sunnyvale, CA). Quantitative RT-
PCR (qRT-PCR) reagent controls (reagents without any template or
with 40 ng non-retro-transcribed RNA) were included in all the
assays. Each assay was run in triplicate and independently repeated
at least three times to verify the results; the mean of all
measurement has been used for analysis and comparisons. The
relative amount of specific transcripts was calculated by the
comparative cycle threshold method given by Schmittgen and
Livak [24]. To correct for sample to sample variations in
quantitative RT-PCR efficiency and errors in sample quantitation,
the level of ACTB transcripts was measured and used in
normalization of specific RNA levels. All the value were made
relative to one of the pancreata and then expressed as relative to the
average of the relative values of the two pancreases. PrimeSTAR
GXL DNA Polymerase from Clontech Laboratories, Inc. (Mountain
View, CA) was used for semiquantitative PCR assays at the
conditions recommended by the manufacturer (supplemental
results). Based on the results of the real-time PCR, the program
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for the amplification of ACTB and INS was set on 30 cycles and the
program for the amplification of VMAT2 was on 36 cycles, with
annealing temperatures of 56–60 °C and extension times of 30–45 s,
depending on the couple of primers used. The custom DNA oligos:
V2-5_F (5′-CGGAAGCTCATCCTGTTCAT-3′) and V2-5_R (5′-
TCTGAGATGGAGGCAGTGTG-3′) specific for Human VMAT2,
as well IN-F (5′-CCGCAGCCTTTGTGAACC-3′) and IN-R (5′-
GCTGGTAGAGGGAGCAGATG-3′) specific for Human INS, were
synthesized by Life Technologies (Grand Island, NY). ACTB primers,
specific for human β-actin, were obtained from QIAGEN
(Hs_ACTB_1_SG QuantiTect Primer Assay Cat No QT00095431).
Statistical Analysis
Descriptive statistics include the arithmetic mean and standard
errors of the mean (S.E.M.). Least-squares linear regression was
used to determine the correlation between outcome measures. The
strength of the correlation is expressed in terms of r2. The
significance of the correlation was calculated using the t distribu-
tion. Student’s t testing was used to assess the significance of the
difference between means. All p values are 2-tailed. Test-retest
reproducibility of PET ROI volume, BPND, and BPND × PET ROI
volume was assessed by calculating variability and reliability. The
within-subject variability was defined as the absolute value of the
difference between test and retest measurements expressed as a
percentage of mean value of test and retest measurements. As
metric of reliability we calculated the intraclass correlation
coefficients (ICC) as previously described [25] using the Shrout
and Fleis model 3,1 [26] according to the following formula.
ICC ¼ MSb−MSw
MSbþ k−1ð ÞMSw
Where MSb and MSw are the mean sum of squares between and
within subjects, respectively, and k is the number of trials or within-
subject measurements (i.e., two in the present study). The
coefficient value ranges from −1 (no reliability) to 1 (maximum
reliability). The standard error of measurement (SEMt) and minimal
detectable change (MDC) at the 95 % confidence interval were









For SEMt calculations, the standard deviation of the biases (i.e.,
test-retest) was used.
Results
Measures of β cell Function
Mixed meal tolerance testing assessed insulin secretion
capacity, which is also a surrogate marker of BCM. AUC
c-peptide and peak c-peptide levels from mixed meal
tolerance testing are reported in Table 2. As expected,
AUC c-peptide and peak c-peptide levels were significantly
lower in patients with long-standing T1DM as compared to
controls (pG0.001). On average, AUC c-peptide for patients
with type 1 diabetes was approximately 3 % the level seen in
healthy controls. Six of eight patients with T1DM had no
detectable c-peptide on mixed meal stimulation. AUC c-
peptide levels in subjects with T2DM were not significantly
different when compared to healthy controls (p=0.18).
Estimation of VMAT2 Binding in Patients and
Controls
Pancreatic VMAT2 binding was compared among patients
and controls. Previous post mortem analysis suggested
VMAT2 binding is most specific to β cells in the body and
tail of the pancreas. Therefore, we report pancreatic BPND in
the body and tail alone (Table 3). Mean BPND in the
pancreatic body and tail was decreased in patients with
T1DM (1.77±0.23) to 74 % of healthy control values (2.39
±0.13) (p=0.023). The functional binding capacity in the
body and tail (i.e., BPND × PET ROI Volume) was decreased
in patients with T1DM (38±6 ml) to 37 % of control subjects
(103±14 ml) (p=0.001). Mean body and tail pancreatic BPND
and BPND × PET ROI volume levels in patients with T2DM
trended lower but were not significantly different from
controls (Fig. 2). We found a significant correlation between
peak c-peptide and functional binding capacity for the entire
study population (Fig. 3).
Test-Retest Characteristics
[18F]FP-(+)-DTBZ pancreatic imaging assessing variability
and reliability was also performed. Two scans were
completed in five healthy control subjects and two patients
with T1DM. Repeat scans were performed less than 1 month
after initial scanning. For measurements of BPND and BPND
× volume, the mean variability was 9.4 % (range=5.0 to
16.5 %) and 16.6 % (range=0.0 to 28 %), respectively. The
ICC reliability scores for the metrics examined ranged from
0.64 to 0.93) (Table 3).
Measurement of Relative Expression Levels of
VMAT2 and Insulin in Pancreas Tissue Samples
Quantification of VMAT2-specific transcripts revealed that
islets express an average of greater than 500-fold more
VMAT2 message than the corresponding exocrine tissue
isolated from the same pancreas. The average fold difference
of expression of VMAT2 in purified islets relative to whole
pancreas was about 40-fold. Quantification of insulin-
specific transcripts revealed a similar fold increase of insulin
message expression in islets relative to exocrine tissue
Table 3. Summary statistics for combined cross-sectional and test-retest studies
β cell function Pancreas body and tail
Cross-sectional
study
AUC (% control) Peak (% control) PET ROI volume
(ml) (% control)
Mean BPND (% control) BPND × Volume
(ml) (% control)
Healthy Controls
Mean 463.43 6.47 43.12 2.39 102.85
S.E.M. 71.44 0.97 4.01 0.13 12.14
T1DM patients
Mean 15.00 (3.2 %) 0.25 (3.8 %) 22.23 (52 %) 1.77 (74 %) 37.81 (37 %)
S.E.M. 9.66 0.10 2.46 0.23 5.56
T2DM patients
Mean 714.67 (154 %) 5.88 (91 %) 30.27 (70 %) 1.93 (81 %) 60.33 (59 %)
S.E.M. 217.07 1.60 5.54 0.42 20.43
Student’s t test (2 tailed) p value of difference
Control vs. T1DM 0.0001 0.0001 0.001 0.022 0.001
Control vs. T2DM 0.18 0.80 0.18 0.20 0.15
Test-retest study
Mean variability 11.70 % 9.40 % 16.60 %
ICC 0.93 0.64 0.88
Standard error of measurement (SEMt) (via SD and ICC) 1.03 0.18 6.48
Minimal detectable change (MDC) (95 %CI) (% control) 2.85 (7 %) 0.49 (20 %) 17.96 (18 %)
Fig. 2 [18F]FP-(+)-DTBZ binding is reduced in the body-tail of the pancreas in T1DM patients vs. healthy control subjects. a
The PET ROI volume, defined as the sum of the volumes of all voxels with a BPND90.1 contained with the combined body-tail of
the pancreas was significantly lower in pancreas of T1DM patients (n=8) relative to controls (n=14). No significant difference
between the PET ROI volume of patients with T2DM and controls was found, but the mean value of the PET ROI volume T2DM
trended lower. b Pancreatic combined body-tail BPND, which reflects tracer-specific binding relative to the VMAT2 poor
reference region (Spleen), was estimated in healthy controls and patients with T1DM or T2DM. The mean BPND was
significantly reduced by 26 % in pancreas of T1DM relative to controls. The mean BPND was not significantly different in the
pancreas of T2DM patients but trended to lower than the values measured in controls. c The functional binding capacity (FBC)
or the product of mean BPND and the PET determined voxel volume for the region was significantly lower (by 63 %) in pancreas
of T1DM patients relative to healthy subjects. The FBC of patients with T2DM was not significantly different but trended to be
lower relative to controls.
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(Fig. 4). The average fold difference of expression of Insulin
expression in purified islets relative to whole pancreas was
about 80-fold.
Discussion
The generally accepted view of the evolution of T1DM
predicts declining BCM beginning in a prodromal period
through diagnosis of disease and ending in the absolute
dependence on exogenous insulin for glucose homeostasis
[28]. In long-standing T1DM disease (95 years), there is
generally a near complete loss of the ability to secrete insulin
[29]. In contrast, the pancreas in T2DM shows variable rates
of β cell loss [30]. Past natural history studies of T1DM or
T2DM or interventional trials have relied on limited autopsy
samples or on multiple non-invasive or minimally invasive
assays to estimate BCM. A shared characteristic of these
latter assays is that they are surrogates, substituting measures
of β cell function for anatomical BCM. These broadly
adopted biomarkers of endocrine pancreas function (a.k.a.
metabolic tests) include blood glucose concentration mea-
surements, stimulated insulin secretion rates, serum insulin
concentrations, HbA1c, and islet/insulin autoantibodies.
These functional BCM biomarkers reflect the complex
multifactorial phenotype of glucose sensing, insulin secre-
tion, and insulin action. As such, they do not routinely assess
potential β cell reserve capacity [31] or functional impair-
ments due to β cell immaturity, dedifferentiation, distress, or
inflammation. Quantitative measures of a simpler β cell
phenotype (e.g., expression of single β cell restricted surface
Fig. 3 Association between binding potential and glucose-
stimulated insulin secretion in controls and patients with
T1DM or T2DM. BPND values and Peak c-peptide measures
for each subject was evaluated for strength of association by
linear correlation.
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receptor) may provide a more accurate estimate of anatom-
ical BCM. In vivo, clinical BCM monitoring is currently
inadequate [32] because it does not reflect BCM in real time,
requires large study populations because of the natural
variability of BCM in humans, reflects confounding comor-
bidities and/or often occur too late (or too early) in the
disease process to be useful sentinels of declining anatomical
BCM. In this study, we have continued our evaluation of
PET-based measurements of pancreatic [18F]FP-(+)-TBZ
uptake and binding to evaluate VMAT2 as a biomarker of
beta cell mass.
Similar to past studies [20, 21], despite significant
reductions in tracer binding in T1DM patients relative to
controls, a greater-than-expected uptake of [18F]FP-(+)-
DTBZ was measured in body and tail of the patients with
T1DM given their almost complete loss of insulin producing
cells. Possible reasons for increased uptake in diabetes
patients include higher than expected non-specific binding,
radioactive metabolites as a confounding source of signal,
and pancreatic sites [33, 34] other than β cells expressing
VMAT2. Preliminary studies by Naganawa [18] suggest that
these sources contribute to less than 15 % of the total tracer
binding however. It is interesting to note that a recent
nuclear medicine study imaging T1DM patients and controls
[35] using an alternative biomarker of BCM, the glucagon-
like peptide 1 receptor (GLP-1R) and an In-111 labeled
exendin-3 radioligand gave results very similar to those
observed for imaging VMAT-2 with [18F]FP-(+)-DTBZ.
Why two very different radioligands, targeting distinctly
different β cell-specific targets, give similar results in both
the fractional decrease in pancreatic binding and a residual
background uptake of the tracer in the T1DM subjects is not
fully understood. Recently, VMAT2 was identified as a late
stage regulator of β cell differentiation [36]. It is tempting to
speculate that the Bbackground^ in our VMAT2 measure-
ments in T1DM may reflect the presence of insulin depleted
mature β cells and/or an immature β cell lineage in the
pancreas.
It is also possible that this residual VMAT2 resides in
ductal and/or exocrine tissue, yet escapes detection by
immunohistochemistry because of low-expression levels.
To explore this possibility, we revisited the question of
VMAT2 expression in the human exocrine pancreas.
Normal beta cell mass (based on immunohistochemistry
measurements) is routinely quoted at being 1–2 % of the
total pancreas ([8, 10] although varies greatly from
individual to individual [7]. We found that the average
fold difference of expression of VMAT2 message in
purified islets relative to whole pancreas was about 40-
fold greater and similar to our previously published results
[37], about 500-fold greater than purified exocrine tissue.
Based on normal beta cell masses ranging from 1 to 2 %,
we would expect that the fold difference between islets and
whole pancreas would range from 100- to 50-fold,
respectively. This possible discrepancy may reflect (a) the
fact that the whole pancreas samples used where not from
the same donors of the islets or (b) non-islet-associated
VMAT2 within the pancreas. However, due to the at least
500-fold greater level of VMAT2 expression in islets
relative to exocrine tissue, the contribution of exocrine
VMAT2 expression to the total VMAT2 expression is
likely to be less than 10 %. Interestingly, even VMAT2
expressed in exocrine tissue might still retain its value as
an indirect marker of BCM, as insulin regulates exocrine
pancreas growth [38].
Two previous reports call into question the utility of
DTBZ-based tracers for PET estimation of pancreatic beta
cell mass [39, 40]. The principal conclusion of Erickson
et al. [39], based on in vitro studies, were that [18F]FE-(+)-
DTBZ (a tracer similar, but not identical, to [18F]FP-(+)-
DTBZ used in the current study) bound to human exocrine
tissue, in both a non-displaceable and displaceable manner,
with a magnitude similar to tracer binding to islet tissue.
These authors also reported the presence of tetrabenazine-
displaceable, low affinity, but high-capacity tracer binding
sites in exocrine tissue homogenates, similar to a report by
Tsao, et al. in a study of [18F]FP-(+)-DTBZ binding to rat
exocrine pancreas tissue homogenates [33]. In a follow-up
in vitro study, Tsao and colleagues, demonstrated that the
low affinity but high-capacity exocrine pancreas tracer
binding sites were likely to corresponded to sigma 1 and 2
receptors based on blocking studies with 1,3-Di-o-
tolylguanidine (DTG) [34]. Fagerholm, et al. [40], in a
study of [11C]-(+)-dihydrotetrabenazine (a ligand with less
affinity to VMAT2 than [18F]FP-(+)-DTBZ) binding to rat
and human pancreas tissue, concluded that binding of [11C]-
(+)-DTBZ and [3H]DTBZ in islets of the rat pancreas did not
exceed the level of binding in exocrine tissue. Contrary to
the studies published by Tsao et al. [33] using [18F]FP-(+)-
DTBZ, Fagerhom et al. were unable to clearly demonstrate
accumulation of either [11C] or [3H]DTBZ radioactivity in
pancreatic islets in situ [40].
Fig. 4 Measurements of relative levels of VMAT2 and insulin-specific transcripts in purified cadaveric islets, exocrine, and
whole pancreas tissue. The relative level of a VMAT2or b Insulin expression was measured in the indicated tissue. The relative
expression levels of VMAT2 or insulin message in the indicated matched samples (Islets 527 (squares), Islets 602 (circles),
purified exocrine 527 (squares), purified exocrine 602 (circles) and unmatched whole pancreas (triangles) (human pancreas total
RNA, LOT 1412464A Clontech) were normalized to one sample of unmatched whole pancreas (diamonds) (human pancreas
total RNA, LOT 06046024 Agilent) and the average relative expression indicated by the black bar.
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The above-cited studies [33, 34, 39, 40] based most of
their conclusions on in vitro studies of tracer binding. The
conclusions of these in vitro studies (i.e., that DTBZ-based
tracers are not suitable for VMAT2 quantification in the
pancreas), however, run contrary to the evidence supplied by
the more relevant in vivo PET studies, performed both in
non-human primates (NHP) [5] and humans [18] using the
(+) and (−) enantiomers of [18F]FP-DTBZ to measure total
and non-specific tracer binding, respectively, in situ. In the
first study, baboons underwent multiple dynamic abdominal
and brain PET scans each for 2 h with (+) and (−)
enantiomers on separate occasions. Data were analyzed by
compartmental models to estimate non-displaceable and
specific VMAT2 binding in the striatum, cerebellum, kidney
cortex, spleen and pancreas. The non-displaceable distribu-
tion volume of [18F]FP-(+)-DTBZ in the pancreas, as
estimated by the total distribution volume of [18F]FP-(−)-
DTBZ in the pancreas, was 25 % or less than the specific
distribution volume. Naganawa et al. [18], using the same
experimental paradigm in human volunteers and NHP,
reported that the non-displaceable distribution volume of
[18F]FP-(+)-DTBZ in the human pancreas, as estimated by
the total distribution volume of [18F]FP-(−)-DTBZ in the
pancreas, was 15 % or less than the specific distribution
volume in humans. To assess possible tracer binding to
sigma receptors, blocking studies in NHP were performed
with fluvoxamine. The extent of displacement by
fluvoxamine of [18F]FP-(+)-DTBZ binding in the pancreas
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was negligible in vivo. Together, these results suggest that
our quantification of pancreatic VMAT2 is reasonably
accurate and not overestimated by significant off-target and
non-specific tracer binding.
In the cross-sectional PET study with [18F]FP-(+)-DTBZ,
we attempted to estimate VMAT2 binding in the pancreas of
healthy controls and patients with type 1 or 2 diabetes
mellitus. As a metric of comparison, we used functional
binding capacity, the product of BPND and volume in the
body and tail of the pancreas. We found that VMAT2
binding was decreased in subjects with long-standing type 1
diabetes when compared to healthy controls. More specifi-
cally, the functional binding capacity in T1DM patients was
37 % of that observed in healthy controls (p=0.001). In
comparison, patients with type 1 diabetes mellitus had on
average 3 % insulin secretion capacity on mixed meal
tolerance testing when compared to healthy controls
(pG0.0001). Our findings are similar to those reported by
Normandin et al. [21]. In their study, the authors also
assessed [18F]FP-(+)-DTBZ PET to compare binding be-
tween long-standing T1DM and healthy controls. The
Normandin study found that pancreatic BPND was reduced
by 40 % (pG0.01) in patients with long-standing T1DM
when compared to healthy individuals matched for age and
BMI. C-peptide was undetectable in all patients with T1DM.
When pancreatic PET volume was used to calculate a
functional binding capacity, total [18F]FP-(+)-DTBZ binding
in the pancreas was reduced by 59 %. We obtained similar
results; functional binding in our study was reduced by
63 %. Normandin and colleagues concluded, as do we, that
quantitative evaluation of islet β cell density using VMAT2
as a biomarker can be achieved using [18F]FP-(+)-DTBZ.
We also assessed pancreatic [18F]FP-(+)-DTBZ uptake in
patients with type 2 diabetes mellitus. To our knowledge,
this is the first pancreatic PET with [18F]FP-(+)-DTBZ study
in T2DM. We found no significant difference in functional
binding capacity in subjects with T2DM when compared to
healthy control (60±20 vs. 102±12 ml, p=0.15). Although
there was no significant difference between these two
groups, functional binding capacity trended lower to 59 %
of controls. This is consistent with autopsy data reported by
Butler et al. [41]. In that study of pancreata from lean or
obese people with or without diabetes, relative pancreatic β
cell volume of diabetic individuals (i.e., insulin dependent)
was approximately 50 % of their non-diabetic counterparts.
Further studies of T2DM and non-diabetic subjects, with a
larger sample size and carefully controlled for adiposity,
medical history, treatment, and family history of T2DM, will
be needed to ascertain the full utility of pancreatic VMAT2
measurements by PET with [18F]FP-(+)-DTBZ in this subset
of patients with diabetes.
We report intra-subject reproducibility of [18F]FP-(+)-
DTBZ in human pancreas. Subjects underwent repeat PET
scanning within 1 month. The reliability of the repeat PET
scans was good-to-excellent and the mean variability
between test and retest scans was about 16 % suggesting
that following repeat scanning, the minimal detectable
change will be around 18 BPND × volume units. If we
arbitrarily set the mean control FBC (103 units) (Table 3) to
represent a BCM of 100 %, at least in the early stages of β
cell decline, the MDC of FBC will roughly correspond to the
minimal detectable percentage change in BCM (i.e., about
18 %).
Conclusion
Pancreatic PET [18F]FP-(+)-DTBZ uptake is significant
reduced in patients with long-standing type 1 diabetes when
compared to healthy controls. Intra-subject test retesting
showed excellent reliability. These results suggest that
longitudinal scanning can be used to track BCM in patients
undergoing β cell loss. Such measurements could expedite
the assessment of therapeutic efficacy of interventions to
onset or treat disease. Further longitudinal studies evaluating
the VMAT2 binding in patients with incipient and newly
diagnosed type 1 diabetes mellitus should be undertaken.
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